Arecor Therapeutics plc (LON:AREC – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday . The stock traded as low as GBX 56 and last traded at GBX 57.50, with a volume of 73844 shares traded. The stock had previously closed at GBX 60.
Arecor Therapeutics Stock Performance
The stock’s 50-day moving average is GBX 63.31 and its 200-day moving average is GBX 68.43. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The stock has a market cap of £22.65 million, a price-to-earnings ratio of 30.00 and a beta of -0.18.
About Arecor Therapeutics
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
